Anhui Lifeon Pharmaceutical Co., Ltd. announced that it will receive CNY 113,000,000 on March 2, 2023. The transaction will include participation from Hefei Lifeon Pharmaceutical Co., Ltd. for CNY 22,600,000. The Company's holdings will decrease from 100% to 49%.

The transaction has been approved in the 4th Meeting of the Company's 5th Directorate and the 4th Meeting of the Company's 5th Supervisory Board and is subject to Company's Shareholders' Approval, The State Administration for Market Regulation issuing Decision on No Implementation of Further Review on Business Concentration Anti-monopoly, Other Necessary Approvals and Huarun Runyao Health Technology (Beijing) Co., Ltd. completes the state-owned assets assessment filing procedures for this capital increase's assessment report. The company has disclosed the post money valuation of CNY 221,568,600. The registered capital of the investor is CNY 72,586,500, and hold 51% stake.